The Primary Biliary Cholangitis Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of ...

The survey of European hepatologists demonstrates the lack of clarity in guidelines. A new survey of European health care centers with expertise in managing primary sclerosing cholangitis (PSC) ...

OCALIVA received FDA accelerated approval in 2016 for the treatment of PBC in adults with an inadequate response to or ...

Primary sclerosing cholangitis is a rare liver complication that can develop among people with inflammatory bowel disease. Early diagnosis can help, but there’s no cure.

Intercept Pharmaceuticals has voluntarily pulled Ocaliva (obeticholic acid) from the US market following a request from the ...

Primary sclerosing cholangitis is a rare, unpreventable liver complication that can happen among people with inflammatory bowel disease.

Intercept Pharmaceuticals has voluntarily removed Ocaliva from the United States market for the treatment of primary biliary ...

– New findings to be presented at the 2025 European Association for the Study of the Liver (EASL) Congress continue to demonstrate the effectiveness of Livdelzi (seladelpar) in reducing pruritus in ...

"Primary Biliary Cholangitis Clinical Trials"DelveInsight's,“Primary Biliary Cholangitis (PBC)- Pipeline Insight, 2025” report provides comprehensive insights about 20+ companies and 25+ pipeline ...

The FDA’s Gastrointestinal Drugs Advisory Committee voted unanimously to recommend accelerated approval of Intercept Pharmaceuticals’ Ocaliva. 1. Ocaliva (obeticholic acid) is intended for the ...

(RTTNews) - The U.S. Food and Drug Administration has granted accelerated approval for Iqirvo (elafibranor) 80 mg tablets for the treatment of primary biliary cholangitis or PBC in combination with ...

Primary sclerosing cholangitis (PSC) is a rare progressive liver disease that damages bile ducts and significantly increases the risk of bile duct cancer, particularly a type called cholangiocarcinoma ...